A/Professor Claudia Nold is a pharmacist by training with broad expertise in cytokine biology, inflammation and immunology. After her graduation from pharmacy school in 2000, she was awarded a competitive three-year PhD Fellowship by the Deutsche Forschungsgemeinschaft (the German NHMRC equivalent) and started her PhD at the Pharmazentrum Frankfurt, Germany. This fellowship entailed a 6-month tenure at the Institute of Asthma and Allergy at the Karolinska Institute, Stockholm, Sweden. From 2006 until 2009 she held a post-doctoral position in Denver, Colorado, USA in the laboratory of Professor Charles A. Dinarello, who first described the function of Interleukin 1.

Some of her achievements of this productive time included the description of anti-viral, endothelial and angiogenic properties of interleukin (IL-)32, and the important paper on the functional differences between monocytes and macrophages (200+ citations). In 2009, A/Prof Nold was recruited to The Ritchie Centre at Hudson Institute of Medical Research in Melbourne, and continued to publish at a very high level, revealing the powerful anti-inflammatory properties of IL-37. In 2011 she was awarded the Christina Fleischmann Award of the International Society of Interferon and Cytokine Research. This award recognizes young female investigators for notable contributions to basic or clinical research. The second achievement exemplifies the translational trajectory that is paramount to her laboratory: her team has almost completed the bedside-to-bench-and-back circuit with their work on interleukin 1 receptor antagonist (IL-1Ra) in bronchopulmonary dysplasia (BPD). There is an urgent medical need to find the first safe and effective treatment for BPD in the neonatal intensive care unit, and the Nold laboratory showed in a mouse model that IL-1Ra prevents the disease. The team is now planning a clinical trial to prove the concept in babies. Because of these innovative programs, the Nold team has been awarded substantial grant funding and an international patent, and are collaborating with partners in the pharmaceutical industry.

Selected publications

  • Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol, March 2015

  • Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, Skuza EM,Veldman A, Berger PJ, Nold-Petry, CA. Interleukin 1 receptor antagonist prevents murine BPD induced by perinatal inflammation and hyperoxia.PNAS 2013, 110(35):14384-89.

  • Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-22.

  • Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF. IL-32 promotes angiogenesis. J Immunol 2014, 192(2):589-602.

  • Zepp JA, Nold-Petry CA, Dinarello CA, Nold MF. Protection from RNA- and DNA-viruses by IL-32. J Immunol 2011, 186(7):4110-8. [featured among 10% best papers in the issue]

  • Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1beta on endothelial cells. Proc Natl Acad Sci USA 106(10):3883-8, March 2009

  • Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113(10):2324-35.